Literature DB >> 26013594

The Role of Drug Exposure in Clinical Development: To What Extent Is Pharmacokinetic Assessment Needed in a Drug Development Programme?

Navin Goyal1.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26013594     DOI: 10.1007/s40262-015-0287-x

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  3 in total

1.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Authors:  Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Rathkopf; Julia Shelkey; Evan Y Yu; Joshi Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John Humm; Steve Larson; Martin Fleisher; Charles L Sawyers
Journal:  Lancet       Date:  2010-04-14       Impact factor: 79.321

2.  Pharmacokinetic Drug Interaction Studies with Enzalutamide.

Authors:  Jacqueline A Gibbons; Michiel de Vries; Walter Krauwinkel; Yoshiaki Ohtsu; Jan Noukens; Jan-Stefan van der Walt; Roelof Mol; Joyce Mordenti; Taoufik Ouatas
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

3.  Clinical Pharmacokinetic Studies of Enzalutamide.

Authors:  Jacqueline A Gibbons; Taoufik Ouatas; Walter Krauwinkel; Yoshiaki Ohtsu; Jan-Stefan van der Walt; Vanessa Beddo; Michiel de Vries; Joyce Mordenti
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.